[go: up one dir, main page]

MX2016010080A - Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer. - Google Patents

Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.

Info

Publication number
MX2016010080A
MX2016010080A MX2016010080A MX2016010080A MX2016010080A MX 2016010080 A MX2016010080 A MX 2016010080A MX 2016010080 A MX2016010080 A MX 2016010080A MX 2016010080 A MX2016010080 A MX 2016010080A MX 2016010080 A MX2016010080 A MX 2016010080A
Authority
MX
Mexico
Prior art keywords
combination
antagonist
treating cancer
ido1 inhibitor
ido1
Prior art date
Application number
MX2016010080A
Other languages
English (en)
Other versions
MX390904B (es
Inventor
Leopold Lance
Kaufman David
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2016010080A publication Critical patent/MX2016010080A/es
Publication of MX390904B publication Critical patent/MX390904B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción describe las terapias de combinación que comprenden un antagonista del receptor de Muerte Programada 1 (PD-1) y un inhibidor selectivo de indolamina 2,3-dioxigenasa 1 (IDO1), y el uso de las terapias de combinación para el tratamiento del cáncer, y en particular para el tratamiento de cánceres que expresan la PD-L1.
MX2016010080A 2014-02-04 2015-02-03 Combinación de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cáncer. MX390904B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935714P 2014-02-04 2014-02-04
PCT/US2015/014247 WO2015119944A1 (en) 2014-02-04 2015-02-03 Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer

Publications (2)

Publication Number Publication Date
MX2016010080A true MX2016010080A (es) 2016-10-07
MX390904B MX390904B (es) 2025-03-21

Family

ID=53778374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010080A MX390904B (es) 2014-02-04 2015-02-03 Combinación de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cáncer.

Country Status (16)

Country Link
US (2) US20170037125A1 (es)
EP (1) EP3102237B1 (es)
JP (2) JP2017508785A (es)
KR (2) KR20220153677A (es)
CN (1) CN106456753B (es)
AU (1) AU2015214404B2 (es)
BR (1) BR112016017700A2 (es)
CA (1) CA2938566A1 (es)
ES (1) ES2856330T3 (es)
IL (1) IL247102B2 (es)
MX (1) MX390904B (es)
NZ (1) NZ722891A (es)
PH (2) PH12020550847A1 (es)
RU (1) RU2744880C1 (es)
SG (2) SG10201806297VA (es)
WO (1) WO2015119944A1 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103130735B (zh) 2005-05-10 2016-08-03 因塞特控股公司 吲哚胺2,3-双加氧酶调节剂及其用法
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
ES2665419T3 (es) 2008-07-08 2018-04-25 Incyte Holdings Corporation 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
CN102470133B (zh) 2009-08-19 2013-08-28 卫材R&D管理有限公司 含有喹啉衍生物的药物组合物
ES2841809T3 (es) 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
EA035037B1 (ru) 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
BR112017002827B1 (pt) 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd Derivado de quinolina altamente puro e método para produção do mesmo
WO2016040880A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
KR102513870B1 (ko) 2014-10-14 2023-03-23 노파르티스 아게 Pd-l1에 대한 항체 분자 및 그의 용도
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
KR20250020678A (ko) * 2015-03-04 2025-02-11 머크 샤프 앤드 돔 엘엘씨 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
EP3311841B1 (en) 2015-06-16 2021-07-28 PRISM BioLab Co., Ltd. Anticancer agent
WO2017011580A2 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
MX2018005600A (es) * 2015-11-04 2018-11-09 Incyte Corp Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
BR112018011228A2 (pt) * 2015-12-01 2019-01-15 Glaxosmithkline Intellectual Property Development Limited tratamentos de combinação e seus usos e métodos
CN106883193B (zh) * 2015-12-15 2021-10-15 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
CN105646389B (zh) * 2016-01-28 2019-06-28 中国科学院上海有机化学研究所 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
EP3398942B1 (en) 2016-02-25 2021-01-27 Shenzhen TargetRx, Inc. Substituted oxadiazole chemical compound and composition containing said chemical compound and use thereof
FI3423087T3 (fi) * 2016-03-04 2023-12-15 Io Biotech Aps Syövän vastainen yhdistelmähoito
CA3015121A1 (en) * 2016-03-04 2017-09-08 Cedars-Sinai Medical Center Polymalic acid based nanoimmunoconjugates and uses thereof
CN107304191B (zh) * 2016-04-20 2023-09-29 上海翰森生物医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2017181849A1 (zh) * 2016-04-20 2017-10-26 江苏豪森药业集团有限公司 吲哚胺2,3-双加氧酶抑制剂及其制备方法与应用
WO2018054365A1 (en) 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
WO2018068201A1 (en) * 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
ES2939646T3 (es) 2016-10-13 2023-04-25 Juno Therapeutics Inc Métodos y composiciones de inmunoterapia que comprenden moduladores de la vía metabólica del triptófano
CN117402852A (zh) 2016-10-14 2024-01-16 精密生物科学公司 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶
TW201815417A (zh) * 2016-10-21 2018-05-01 蘇州盛迪亞生物醫藥有限公司 Ｐｄ－１抗體與ｉｄｏ抑制劑聯合在製備抗腫瘤的藥物中的用途
CN108218807A (zh) * 2016-12-22 2018-06-29 上海长森药业有限公司 一种作为吲哚胺-2,3-双加氧酶抑制剂的砜脒及其制备方法和用途
EP3842442B1 (en) 2016-12-22 2023-11-01 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
CA3047002A1 (en) 2017-01-17 2018-07-26 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
CN108794423B (zh) * 2017-04-27 2022-07-19 鲁南制药集团股份有限公司 亚氨脲衍生物
CN110831597A (zh) 2017-05-16 2020-02-21 卫材R&D管理有限公司 肝细胞癌的治疗
EP3630807B1 (en) 2017-05-25 2025-08-13 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
CN109081818B (zh) * 2017-06-14 2022-04-22 南京华威医药科技集团有限公司 新型吲哚胺2,3-双加氧化酶抑制剂
CN110769857A (zh) * 2017-06-20 2020-02-07 塔弗达治疗有限公司 包含靶向治疗剂的联合疗法
EP3421607A1 (en) * 2017-06-29 2019-01-02 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Identification and elimination of damaged and/or senescent cells
CN109206380A (zh) * 2017-07-03 2019-01-15 上海时莱生物技术有限公司 吲哚胺2，3-双加氧酶抑制剂化合物及其制备方法和用途
MX2020002301A (es) * 2017-09-13 2020-07-13 Five Prime Therapeutics Inc Terapia de combinacion de anticuerpos anti receptor del factor estimulante de colonias 1 (csf1r) y anti proteina de muerte programada 1 (pd-1) combinados para cancer pancreatico.
CN109897011B (zh) * 2017-12-08 2023-10-31 上海华汇拓医药科技有限公司 一类ido抑制剂及其应用
KR102492115B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 2'3' 사이클릭 다이뉴클레오티드
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
US11713353B2 (en) 2018-01-15 2023-08-01 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against PD-1
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
AU2018410849B2 (en) 2018-02-27 2025-02-27 Leidos, Inc. PD-1 peptide inhibitors
CN110221068B (zh) * 2018-03-02 2020-09-18 中国医学科学院基础医学研究所 检测Kyn含量的试剂的应用
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
US11071730B2 (en) 2018-10-31 2021-07-27 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CN111617078B (zh) * 2019-02-28 2023-02-03 四川科伦博泰生物医药股份有限公司 用于疾病治疗和/或预防的药物组合物、方法及其用途
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
AU2020231201B2 (en) 2019-03-07 2025-02-20 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972696A1 (en) 2019-05-22 2022-03-30 Leidos, Inc. Lag3 binding peptides
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021062018A1 (en) * 2019-09-25 2021-04-01 Bristol-Myers Squibb Company Composite biomarker for cancer therapy
EP4037708B1 (en) 2019-09-30 2024-09-18 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
EP4041402A1 (en) 2019-11-12 2022-08-17 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing ido antagonist prodrugs useful in the treatment of cancer and methods thereof
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US11338040B2 (en) 2020-06-04 2022-05-24 Leidos, Inc. Immunomodulatory compounds
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CA3189692A1 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
CA3198203A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
KR20230152715A (ko) * 2021-03-05 2023-11-03 유니버시타트 바셀 Ebv 관련 질환 또는 질병의 치료용 조성물
EP4052705A1 (en) * 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
TW202348237A (zh) 2021-05-13 2023-12-16 美商基利科學股份有限公司 TLR8調節化合物及抗HBV siRNA療法之組合
TWI883332B (zh) 2021-06-11 2025-05-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗癌劑之組合
JP7673255B2 (ja) 2021-06-11 2025-05-08 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗体薬物コンジュゲートとの組み合わせ
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN116444454B (zh) * 2023-06-16 2023-09-12 中国医学科学院医药生物技术研究所 N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
TW202544019A (zh) 2024-05-13 2025-11-16 美商基利科學股份有限公司 組合療法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
RU2406760C3 (ru) 2005-05-09 2017-11-28 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EA019344B1 (ru) 2005-07-01 2014-03-31 МЕДАРЕКС, Эл.Эл.Си. Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
ES2665419T3 (es) * 2008-07-08 2018-04-25 Incyte Holdings Corporation 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
EP3530672B1 (en) 2008-09-26 2024-05-01 Dana-Farber Cancer Institute, Inc. Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
KR101050829B1 (ko) * 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
ES2974437T3 (es) 2008-12-09 2024-06-27 Hoffmann La Roche Anticuerpos ANTI-PD-L1 y su uso para mejorar la función de las células T
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2012135401A1 (en) * 2011-03-29 2012-10-04 Dow Global Technologies Llc Method for making porous mullite-tialite composites
WO2012135408A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
UA117220C2 (uk) 2011-08-01 2018-07-10 Дженентек, Інк. Способи лікування раку з використанням антагоністів, що зв'язуються з віссю pd-1, і інгібіторів mek
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
US9321755B2 (en) * 2013-11-08 2016-04-26 Incyte Corporation Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor

Also Published As

Publication number Publication date
SG11201606428UA (en) 2016-09-29
PH12016501550A1 (en) 2016-10-03
KR20220153677A (ko) 2022-11-18
US20190270812A1 (en) 2019-09-05
CN106456753A (zh) 2017-02-22
IL247102B2 (en) 2023-07-01
PH12016501550B1 (en) 2021-10-01
MX390904B (es) 2025-03-21
JP2017508785A (ja) 2017-03-30
NZ722891A (en) 2021-07-30
SG10201806297VA (en) 2018-08-30
EP3102237A1 (en) 2016-12-14
RU2744880C1 (ru) 2021-03-16
JP6812512B2 (ja) 2021-01-13
IL247102A0 (en) 2016-09-29
AU2015214404B2 (en) 2020-10-01
CA2938566A1 (en) 2015-08-13
US20170037125A1 (en) 2017-02-09
JP2019214589A (ja) 2019-12-19
CN106456753B (zh) 2021-05-11
ES2856330T3 (es) 2021-09-27
PH12020550847A1 (en) 2022-05-11
BR112016017700A2 (pt) 2017-10-10
AU2015214404A1 (en) 2016-08-18
EP3102237A4 (en) 2017-08-02
IL247102B1 (en) 2023-03-01
EP3102237B1 (en) 2020-12-02
HK1232153A1 (en) 2018-01-05
WO2015119944A1 (en) 2015-08-13
KR20160108568A (ko) 2016-09-19

Similar Documents

Publication Publication Date Title
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
CY1124785T1 (el) Συνδυασμος ανταγωνιστη toy pd-1 και αναστολεα toy vegfr για την αντιμετωπιση του καρκινου
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
MX2017005553A (es) Terapia de combinacion para cancer.
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
PH12017501857B1 (en) Pd-l1 antagonist combination treatments
MX2017015308A (es) Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
MX393976B (es) Inhibidores de muerte programada 1 (pd-19) /ligando de muerte programada 1 (pd-l1) para el tratamiento de cáncer.
MX2018013593A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1.
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
BR112017017700A2 (pt) métodos, composições e kits para tratamento do câncer
CL2018003444A1 (es) Derivados de adenosina para uso en el tratamiento del cancer.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
CO2018007239A2 (es) Reguladores de ctfr y métodos de uso de los mismos
CO2018007237A2 (es) Reguladores del cftr y métodos para su uso
AR100289A1 (es) Formas de un inhibidor de pi3k
CO2018007236A2 (es) Reguladores cftr y métodos de uso
CO2017005741A2 (es) Compuestos para tratar el cáncer